Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

(Loss) Income per Common Share

(Loss) Income per Common Share

3 Months Ended

Feb. 29, 2016

Note 8 – (Loss) Income per Common Share

Net (loss) income per common share data are based on net income. The following table sets forth the calculation of basic and diluted (loss) earnings per share:


	For the three months ended February 29, 2016			For the three months ended February 28, 2015
Numerator:
Net (Loss) Income	($	122,936	)	$	286,170
Denominator:
Weighted-average shares outstanding-basic		8,971,373			9,824,566
Dilutive common shares issuable upon exercise of stock options		—			234,083
Weighted-average shares-diluted		8,971,373			10,058,649

(Loss) Earnings per share:
Basic	($	0.01	)	$	0.03

Diluted	($	0.01	)	$	0.03

For the three months ended February 29, 2016, the Company excluded the effect all outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive. For the three months ended February 28, 2015, the Company excluded the effect of 271,000 outstanding stock options from the computation of diluted earnings per share, as the effect of potentially dilutive shares from the outstanding stock options would be anti-dilutive.